Navigation Links
Nutra Pharma Introduces Chronic Pain Reliever, Nyloxin OTC, for International Distribution
Date:11/19/2009

Nutra Pharma has introduced Nyloxin OTC, an over-the-counter pain reliever, that will be marketed and sold through international distribution channels alongside the Company's prescription pain reliever, Nyloxin Rx.

Plantation, FL (Vocus) November 19, 2009 -- Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today the introduction of Nyloxin OTC for the treatment of chronic pain. Nyloxin OTC will be marketed and sold internationally alongside the Company's prescription pain reliever, Nyloxin Rx.

"Nyloxin OTC is an important addition to our line of pain relievers and offers many benefits similar to that of Cobroxin, our over-the-counter pain reliever currently being marketed and sold in the United States" explained Dr. Paul Reid, CEO of ReceptoPharm. "By introducing our pain relievers internationally under a single, unified brand, Nyloxin, we can better leverage our growth overseas as we complete the required registrations and build awareness for both our prescription pain reliever, Nyloxin Rx, as well as our over-the-counter pain reliever, Nyloxin OTC," he added.

Nutra Pharma recently announced its intention to begin the drug registration process for its pain relievers in Canada, Europe, and South America. The Company expects to have these registrations completed in the near term and plans to subsequently launch Nyloxin Rx and Nyloxin OTC in those territories through select international licensees.

"The international pain market represents a significant growth opportunity for our company, especially in countries where there is limited access to opiate-based medicines," explained Rik J Deitsch, Chairman and CEO of Nutra Pharma. "With the introduction of Nyloxin OTC, we now believe we can offer a more well-rounded product line that covers a much broader spectrum of the pain management market," he concluded.

Nyloxin OTC, which was developed by Nutra Pharma's wholly-owned drug discovery subsidiary, ReceptoPharm, will be available as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis.

About Nutra Pharma Corp.
Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's subsidiary, ReceptoPharm, Inc., is developing these technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics, is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Paratuberculosis (para-TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.

http://www.NutraPharma.com
http://www.ReceptoPharm.com
http://www.Nyloxin.com

SEC Disclaimer
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). Introducing Nyloxin OTC for international distribution should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

# # #

Read the full story at http://www.prweb.com/releases/Nutra_Pharma/Nyloxin_OTC/prweb3231994.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Nutra Pharma Announces Plans to Begin Drug Registration Process in South America for its Over-the-Counter Pain Reliever
2. Vivakor Presents at Nutraceutical Event
3. Reportlinker Adds US World Nutraceutical Ingredients Industry
4. RZN Nutraceuticals Receives United States Patent & Trademark Office Notice of Allowance for Proprietary HerbaZorb(TM) Absorption and Delivery System Technology Used in Popular Arthri-Zen Relief(R) and Migra-Zen Relief PLUS(R) Products
5. Star Scientific Files Second Quarter Financial Results; Rock Creek Pharmaceuticals Reports Early Promising Results in Studies Assessing Safety and Viability of Active Components for a Non-Nicotine Nutraceutical (CigRx(TM))
6. NutraCea Announces Forbearance Agreement With Bank and Provides Update on Business Strategy and Transactions
7. NutraCea Announces Additions to Management Team; Chief Operating Officer Extends Employment Contract
8. Nutraceutical Reports Fiscal 2009 Q3 Results and Expands Share Repurchase Program
9. HBA X-Ceuticals Conference Explores The Emerging Market of Cosmeceuticals and Nutraceuticals
10. Nutrition 21 Launches New Innovative PRESCRIPTIX(TM) Nutraceuticals Product Line
11. Synutra Annual Report on Form 10-K Includes Going Concern Explanatory Paragraph from Auditor
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Nutra Pharma Introduces Chronic Pain Reliever, Nyloxin OTC, for International Distribution
(Date:5/23/2017)... ... May 23, 2017 , ... Therachat , a ... survey in an infographic on the current state of anxiety in support of National ... anxiety, was conducted in April 2017 and benchmarked general anxiety levels as well as ...
(Date:5/22/2017)... Kisco, NY (PRWEB) , ... May 22, 2017 , ... ... are urged to receive relaxing sedation dentistry in Mt. Kisco, NY from Advanced Endodontics ... be administered for a variety of treatments. One or more sedation methods may be ...
(Date:5/22/2017)... PITTSBURGH, PA (PRWEB) , ... May 22, 2017 , ... ... way to write with a pen. "My wife’s hand was damaged in a firework ... invent something that helps people with manual problems." , He then designed and created ...
(Date:5/22/2017)... ... 22, 2017 , ... Faithfully following pop culture, people today are forever in ... shaped through fitness programs. It carries on to skin nourished, pampered and nurtured to ... radiant smile. CDA has found that just like a perfectly cut and ...
(Date:5/21/2017)... ... May 19, 2017 , ... Chris Cornell, 52, was found dead on the night of Wednesday, ... most respected lead singers in the rock industry would take his own life, but the ... investigates how mental illness played a role in the death of Chris Cornell . ...
Breaking Medicine News(10 mins):
(Date:5/18/2017)...  Two Bayer U.S. Pharmaceutical leaders received top awards ... 28 th Woman of the Year ... longstanding mission of furthering the advancement and impact of ... Cindy Powell-Steffen , senior director of brand activation and ... Libby Howe , a regional business manager for New ...
(Date:5/15/2017)... 2017 Enterin Inc., a privately-held CNS pharmaceutical company ... compounds to treat Parkinson,s disease (PD), has enrolled the first ... 1/2a randomized, controlled, multicenter study involving patients with PD and ... patients over a 9-to-12-month period. The first stage is open ... PD. Participating sites include Denver , ...
(Date:5/10/2017)... -- Hologic, Inc. (Nasdaq: HOLX ) announced ... quarter ended April 1, 2017 .   GAAP diluted ... to the prior year period as the sale of ... while non-GAAP diluted EPS of $0.50 increased 6.4%.  Revenue ... currency terms.  Excluding the effects of blood screening and ...
Breaking Medicine Technology: